Möchten Sie immer auf dem neuesten Stand bleiben?

SYDNEY, AUSTRALIA--(Marketwired - May 29, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), a leading immuno-oncology company, today announced that it has made...

SYDNEY, AUSTRALIA--(Marketwired - May 27, 2015) - Editors and readers are advised to disregard the duplicate news release with the headline, "CVac Shows Clear Trend for Overall Survival Benefit in...

SYDNEY, AUSTRALIA--(Marketwired - May 26, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Final Data from the CAN-003 Phase II trial after 5 years of data...

SYDNEY, AUSTRALIA--(Marketwired - May 19, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Final Data from the CAN-003 Phase II trial after 5 years of data...

SYDNEY, AUSTRALIA--(Marketwired - May 14, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) Highlights: Agreement reached with Ridgeback Capital Investments, a...

SYDNEY, AUSTRALIA--(Marketwired - May 11, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces a collaboration with NEC Corporation and Yamaguchi University for...

SYDNEY, AUSTRALIA--(Marketwired - Mar 2, 2015) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) Highlights Prima to focus on developing its highly prospective...

SYDNEY, AUSTRALIA--(Marketwired - Jan 28, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company") announces the first dosing of a subject by GSK in a Phase 1, first-in-human...

SYDNEY, AUSTRALIA--(Marketwired - Jan 20, 2015) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima") is pleased to advise that it has received approximately $777k in a cash rebate from the...

SYDNEY, AUSTRALIA--(Marketwired - Dec 29, 2014) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), announces that it received a notice, dated December 23, 2014 (the "Notice"),...